Sodium Bicarbonate Injection · 308 days since initial FDA posting
FDA lists Sodium Bicarbonate Injection as To Be Discontinued (Hospira, Inc., a Pfizer Company).
No availability text on this FDA row.
Sodium Bicarbonate Injection: To Be Discontinued
FDA availability text is not recorded on this row. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Sodium Bicarbonate Injection
- Manufacturer
- Hospira, Inc., a Pfizer Company
- Dosage Form
- Injection
- Presentation
- Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 0409-5534-14)
- Package NDC
- 0409-5534-14
Status & Timeline
- Status
- To Be Discontinued
- First Reported
- Nov 7, 2025
- Last Updated
- Nov 7, 2025
- Therapeutic Category
- Endocrinology/Metabolism, Gastroenterology, Pediatric
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Discontinuation of the manufacture of the drug
Nearby, Other Sodium Shortage Records
Sodium Bicarbonate Injection
Fresenius Kabi USA, LLC
Injection
Sodium Bicarbonate Injection
Fresenius Kabi USA, LLC
Injection
Sodium Bicarbonate Injection
Hospira, Inc., a Pfizer Company
Injection
Sodium Bicarbonate Injection
Hospira, Inc., a Pfizer Company
Injection
Sodium Bicarbonate Injection
Hospira, Inc., a Pfizer Company
Injection
Sodium Bicarbonate Injection
Hospira, Inc., a Pfizer Company
Injection
FDA reason on file: Discontinuation of the manufacture of the drug. General shortage guidance lives on the tracker hub.